Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zimberelimab · AB-122, GLS-010

Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PDCD1) · developed by Gilead Sciences

Phase 2 Most advanced trial

GILD Developer

2 Registered trials

What is Zimberelimab?

Zimberelimab is a fully human IgG4 monoclonal antibody that binds the immune checkpoint receptor PD-1 (PDCD1), blocking its interaction with PD-L1 and PD-L2 and its downstream signaling to restore T-cell activation. It is studied in gastrointestinal tract malignancies and prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AB-122, GLS-010
Drug type: Monoclonal antibody
Targets: Programmed cell death protein 1 (PDCD1)
Mechanism: Inhibitor of Programmed cell death protein 1 (PDCD1)
Pathways: PD-1 downstream signaling, T-cell activation
Therapy area: Oncology
Developer: Gilead Sciences (GILD)
Also in trials of: CHRS
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: ZBL7O904IL

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05329766	Phase 2	Gastrointestinal Tract Malignancies	Active not recruiting	GILD
NCT05177770	Phase 2	Metastatic Castration-resistant Prostate Cancer	Terminated	CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastrointestinal Tract MalignanciesMetastatic Castration-resistant Prostate CancerProstate Cancer

Other drugs acting on PDCD1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1 Geptanolimab Phase 1/2

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Zimberelimab

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z